Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

MacKenzie Anderson

Interventional Pain Medicine Kansas City, KS Nurse Practitioner

NPI 1811729866 CMS profile 11627507

4000 Cambridge St, Kansas City, KS 66160

Open in the dashboard

General payments

$4,318

36 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, MacKenzie Anderson of Kansas City, KS is reported in the CMS Open Payments database as having received $4,318 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,537 28
2024 General $781 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • MacKenzie Anderson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to MacKenzie Anderson were reported at $3,537. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year MacKenzie Anderson Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $781 $684 $206–$1,837 $164
2025 $3,537 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Saluda Medical Americas, Inc. $2,573 9 payments
  2. Globus Medical, Inc. $327 13 payments
  3. BIOTRONIK NRO, Inc. $315 2 payments
  4. Nevro Corp. $286 3 payments
  5. Averitas Pharma Inc. $225 2 payments
  6. SPR Therapeutics, Inc $183 2 payments
  7. Nalu Medical, Inc. $118 1 payment
  8. Spinal Simplicity, LLC $117 1 payment
  9. Pfizer Inc. $82 1 payment
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $70 1 payment
  11. Other $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,530 35 payments
  2. Travel and Lodging $1,788 1 payment
Products named General payments · program years 2024–2025
  1. Evoke $2,573 9 payments
  2. Senza Spinal Cord Stimulator $327 13 payments
  3. Prospera $315 2 payments
  4. Senza Spinal Cord Stimulator $286 3 payments
  5. Qutenza $225 2 payments
  6. SPRINT PNS System $183 2 payments
  7. Nalu Neurostimulation System $118 1 payment
  8. HA MINUTEMAN G3-R $117 1 payment
  9. NURTEC ODT $82 1 payment
  10. RELISTOR $70 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record